Of note, although growing evidence indicated the selective targeting of Notch4 of therapeutic relevance in certain tumors, including the ER+ metastatic hormone-refractory breast cancer, no Notch4-blocking antibodies are under clinical investigation. The gene discussed is ESR1; the disease is breast carcinoma.